100. Why AngioDynamic’s AMBITION BTK RCT Study Changes Everything

This week’s episode features Dr. John H. Rundback, Director of the Interventional Institute at Holy Name Medical Center and one of the most experienced voices in complex peripheral work.Dr. Rundback joins Miguel and Lucas for a conversation on how below-the-knee disease has changed, why operators rely on different tools and access strategies today, and what the AMBITION BTK clinical trial aims to clarify about treating BTK patients.03:09 How BTK and below-the-ankle disease differ from proximal disease05:28 What pushed operators toward atherectomy in BTK care06:56 Introducing AngioDynamics and the AMBITION BTK trial10:49 How the Auryon laser works and what makes it different14:44 Why early results led to launching the AMBITION BTK study20:06 How high-volume operators identify meaningful patterns early23:28 Tips and workflow for using the Auryon laser below the knee29:12 Why Miguel now uses primary pedal access in many BTK cases37:30 How the AMBITION BTK trial uses a hierarchical win-ratio endpointWho Should ListenThis episode is relevant for clinicians who treat below-the-knee disease, early-career physicians interested in real-world atherectomy decision making, and professionals involved in device evaluation, trial design, and BTK care pathways.About John H. Rundback, MDJohn H. Rundback, MD, is a renowned interventional radiologist in practice since 1993 and is the Director of the Interventional Institute at Holy Name Medical Center. He is board-certified in radiology and holds a Certificate of Added Qualification in Angiography and Interventional Radiology. He has been named as a Top Doctor by Castle Connolly.Dr. Rundback's research interests include peripheral arterial, carotid, and aortic aneurysmal disease, deep venous thrombosis and varicose veins, as well as state-of-the-art minimally invasive cancer therapies, and he is the principal investigator on a number of multi-center trials. He has presented at more than 200 conferences and is the program chairman for his own peripheral arterial disease symposium. He has served as an editor and reviewer for peer-reviewed medical journals and has published over 100 articles.Dr. Rundback is a past member of the Board of Directors of the Society of Interventional Radiology Foundation and Founding Chair for the Foundation's Cooperative Alliance for Interventional Research Clinical Trials Network. At Holy Name, he serves on the Patient Safety Committee, the Cancer Committee and the Credentialing Committee.Dr. Rundback earned his medical degree from SUNY Downstate Medical Center, after which he completed his internship at St. Vincent's Hospital and Medical Center, New York, N.Y.Connect with John💼 LinkedIn: John H. Rundback, MDAbout AngioDynamics Established in 1988, as a division of E-Z-EM, AngioDynamics is a company with a rich history that’s defined by its innovation and growth as a committed medical community partner with a focus on developing high-quality medical devices that improve patient outcomes.The company’s commitment to advancing medical solutions has established a strong presence in key healthcare markets worldwide. Through strategic partnerships, distribution networks, and a diverse product portfolio, AngioDynamics continues to contribute to the improvement of patient outcomes on a global scale.AngioDynamics has a notable global presence, with worldwide operations.Learn more about Angiodynamics and the Auryon System🌐 Websites: angiodynamics.com & auryon-system.comFollow Life of Flow📲 Instagram: ⁠⁠@LifeofFlowPodcast⁠⁠👍 Facebook: ⁠⁠Life of Flow Podcast⁠⁠💼 LinkedIn: ⁠⁠Life of Flow Podcast⁠⁠🐦 X: ⁠⁠@VascularPodcastIf this episode gave you a clearer view of BTK care, share it with someone who’d value it. And if you’re enjoying Life of Flow, a quick review helps others find conversations like this!